ICMJE DISCLOSURE FORM

Date: **Oct 12th, 2021**

Your Name: **Jeffrey L. Platt, M.D.**

Manuscript Title: **Regional delivery of immunosuppression for transplantation of vascularized composite allografts: opportunities near and far**

Manuscript number (if known): **ATM-2021-15**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | National Institutes of Health (AI151588)(USA)                                     |
|   |                                                                                               | Department of Defense (RT190021)(USA)                                             |
|   |                                                                                               | **Time frame: Since the initial planning of the work**                             |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                      | RO1AI122369 (Platt PI; Fox PI) Hepatocyte xenografts for treatment of acute liver failure Current support, unrelated |
|   |                                                                                               | RO1OD023138 (Piedrahita PI; Platt Co-PI) Immunodeficient pigs for stem cell based regenerative medicine Current support, unrelated |
|   |                                                                                               | R21 AI159219 (Cascalho PI; Platt PI) TNRSF13B polymorphisms and the control of innate B cell Current support, unrelated |
|   |                                                                                               | **Time frame: past 36 months**                                                    |
|   |   |   |   |
|---|---|---|---|
|   | responses – a double edged sword |   |   |
|   | W81XWH-18-1-0721 (DoD PRMRP) Mutable vaccines for emerging infectious threats | Current support, unrelated |   |
|   | Takeda (Millennium Pharm) (Djamali - U Wis PI; Platt and Cascalho - U Mich co-I) IXADES STUDY | Current support, unrelated |   |
| 3 | Royalties or licenses | _x_ None |   |
| 4 | Consulting fees | _x_ None |   |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | UpToDate | unrelated |
|   |   | MDPI-IJMS | Editor in chief |
| 6 | Payment for expert testimony | _x_ None |   |
| 7 | Support for attending meetings and/or travel | _x_ None |   |
| 8 | Patents planned, issued or pending | US20090138976 | unrelated |
|   |   | PCT/US04/18859 | unrelated |
|   |   | PCT/US04/012058 | unrelated |
|   |   | US20110107441 A1 and Canada: CA 2558012 | unrelated |
|   |   | WO2005086698 A3 | unrelated |
|   |   | US2008003853 | unrelated |
|   |   | PCT/US06/00864 | unrelated |
|   |   | US 8,153,592 | unrelated |
|   |   | US 34733US1Pro | unrelated |
|   |   | OTT Ref. No.: 2019-005 | unrelated |
|   |   | OTT Ref. No.: 2020-359 | unrelated |
|   |   | OTT Ref. No.: 2021-077 | unrelated |
|   |   | OTT Ref. No.: 2021-043 | unrelated |
|   |   | OTT Ref. No.: 2021-078 | unrelated |
|   |   | OTT Ref. No.: 2021-498 | unrelated |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _x_ None |   |
| 10 |   | _x_ None |   |
|   | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid |   |
|---|-------------------------------------------------------------------------------------------------|---|
| 11 | Stock or stock options | _x_ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _x_ None |
| 13 | Other financial or non-financial interests | _x_ None |

Please summarize the above conflict of interest in the following box:

I have grant funding related to VCA (W81XWH-20-10943 DoD/CDMRP).

Please place an “X” next to the following statement to indicate your agreement:
_x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

[Signature]

[Date]
ICMJE DISCLOSURE FORM

Date:  _Oct 12th, 2021_

Your Name:  _Marilja Cascalho_

Manuscript Title:  _Regional delivery of immunosuppression for transplantation of vascularized composite allografts: opportunities near and far_

Manuscript number (if known):  _ATM-2021-15_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | National Institutes of Health (AI151588)(USA)  
Department of Defense (RT190021)(USA) |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | R21 AI159219 (Cascalho PI; Platt PI) TNRSF13B polymorphisms and the control of innate B cell responses – a double edged sword  
Takeda (Millenium Pharm) (Djamali - U Wis PI; Platt and Cascalho - U Mich co-I) IXADES STUDY | Current support -unrelated  
Current support -unrelated |
| 3 | Royalties or licenses | _x_ None |
|   |   |   |
|---|---|---|
| 4 | Consulting fees | _x_ None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _x_ None |
| 6 | Payment for expert testimony | _x_ None |
| 7 | Support for attending meetings and/or travel | _x_ None |
| 8 | Patents planned, issued or pending | US 7776321 B2 unrelated |
|   |   | PCT US 011/34733 unrelated |
|   |   | Disclosure #2021-01179 unrelated |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _x_ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _x_ None |
| 11 | Stock or stock options | _x_ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _x_ None |
| 13 | Other financial or non-financial interests | _x_ None |

**Please summarize the above conflict of interest in the following box:**

I have grant funding related to VCA (W81XWH-20-10943 DoD/CDMRP).
Please place an “X” next to the following statement to indicate your agreement:

_x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date:  **Oct 12th, 2021**

Your Name:  **Christina L. Kaufman PhD**

Manuscript Title:  **Regional delivery of immunosuppression for transplantation of vascularized composite allografts: opportunities near and far**

Manuscript number (if known):  **ATM-2021-15**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
|1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | __x__ None |
|   | **Time frame: Since the initial planning of the work** | |
|2 | Grants or contracts from any entity (if not indicated in item #1 above). | W81XWH-20-10943 DoD/CDMRP |
|3 | Royalties or licenses | __x__ None |
|4 | Consulting fees | __x__ None |
|5 | | __x__ None |
|   | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events |   |
|---|-------------------------------------------------------------------------------------------------|---|
| 6 | Payment for expert testimony                                                                    | _x_ None |
| 7 | Support for attending meetings and/or travel                                                    | _x_ None |
| 8 | Patents planned, issued or pending                                                               | _x_ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                                | VCA patient review |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | Treasurer of Board, American Society of Reconstructive Transplantation (ASRT) |
| 11| Stock or stock options                                                                            | _x_ None |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services                 | _x_ None |
| 13| Other financial or non-financial interests                                                        | _x_ None |

Please summarize the above conflict of interest in the following box:

I have no personal financial conflicts but I am involved in review of VCA patients and in scientific and clinical societies related to VCA, and have grant funding related to VCA (W81XWH-20-10943 DoD/CDMRP).

Please place an “X” next to the following statement to indicate your agreement:

_ _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.